Ahmedabad-based Intas announced the launch of Thymotas – a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard Covid-19 treatment.
Thymoquinone (Thymotas) is the active biological component of Nigella sativa (also known as Kalonji, Black Cumin (Kali Jeeri)). There are various scientific publications available that prove Thymoquinone’s multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized, and ready-to-use tablet by Intas said to be for the first time in the world.
According to the company, Thymotas fortifies immunity and fights infections through multimodal actions such as anti-viral, anti-bacterial, anti-inflammatory, immunomodulatory, and antioxidant. Thymotas’ anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and have tremendous potential as a potent add-on to the standard treatment in Covid-19.
Dr Alok Chaturvedi, senior vice-president and head-Medical Affairs said, “In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively.”
Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster and prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg a day after meals based on the severity of infection or directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.
Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing companies globally. The company has set up a network of subsidiaries, under the name Accord Healthcare, for marketing and selling in the highly regulated markets of EU, US, Canada, South Africa, Australia, Asia Pacific, and CIS & MENA regions. Intas is present in 85+ countries worldwide, with more than 69% of its revenue from global business, particularly the highly regulated EU and US markets.
Currently ranked 8th (as per IQVIA TSA MAT September 2020) in the Indian pharmaceutical market, it is also one of the largest privately-owned Indian generic pharmaceutical companies. While Intas has established leadership in key therapeutic segments like CNS, cardiovascular, diabetology, gastroenterology, urology, and oncology in India, the company is known for its range of products in oncology and other hospital-based therapeutic segments in the EU and US.